MediciNova Stock (NASDAQ:MNOV)
Previous Close
$1.90
52W Range
$1.12 - $2.55
50D Avg
$1.82
200D Avg
$1.49
Market Cap
$95.64M
Avg Vol (3M)
$79.48K
Beta
0.77
Div Yield
-
MNOV Company Profile
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
MNOV Performance
Peer Comparison
Ticker | Company |
---|---|
CYT | Cyteir Therapeutics, Inc. |
PMVP | PMV Pharmaceuticals, Inc. |
AVTE | Aerovate Therapeutics, Inc. |
ACRV | Acrivon Therapeutics, Inc. Common Stock |
CSBR | Champions Oncology, Inc. |
ANTX | AN2 Therapeutics, Inc. |
PHVS | Pharvaris N.V. |
RZLT | Rezolute, Inc. |
PEPG | PepGen Inc. |
ANEB | Anebulo Pharmaceuticals, Inc. |
ADAG | Adagene Inc. |
MOLN | Molecular Partners AG |
ELYM | Eliem Therapeutics, Inc. |